DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer.
Li, X., Liang, L., Zhu, Z., Hua, H., Qiu, Y.(2025) Cancer Biol Med 22: 231-236
- PubMed: 40110648 
- DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0586
- Primary Citation of Related Structures:  
8YRY - Department of Research and Development, Duality Biologics, Ltd., Shanghai 201204, China.
Organizational Affiliation: 


















